Haemopneumonia
| Haemopneumonia | |
|---|---|
| Synonyms | Haemopneumonitis, Haemoplague |
 | |
| A man in Trenshaya, Velesa, suffering from the later stages of the Haemopneumonia bacterial infection | |
| Pronunciation | |
| Specialty | Pulmonology, Haematology, infectious disease |
| Symptoms | Cough, difficulty breathing, rapid breathing, fever, prolonged bleeding |
| Duration | Few weeks |
| Causes | Haemopneumonia-causing bacteria |
| Risk factors | Cystic fibrosis, COPD, asthma, diabetes, heart failure, history of smoking, older age |
| Diagnostic method | Based on symptoms, chest X-ray |
| Differential diagnosis | COPD, asthma, pulmonary edema, pulmonary embolism, pulmonary hemorrhage |
| Prevention | Handwashing, social distancing/quarantine, face coverings, vaccines |
| Medication | Antibiotics, oxygen therapy |
| Frequency | 450 million (7%) per year |
| Deaths | Four million per year |
Haemopneumonia (also known as the Haemoplague) is an inflammatory and hemorrhagic condition of the lung primarily affecting the alveoli, upper respiratory tract, and trachea. Initial symptoms include a combination of productive or dry cough, chest pain, fever, and difficulty breathing. Later symptoms include a cough productive of blood (hemoptysis) and worsening of oxygenation leading to cyanosis.
Haemopneumonia is caused by infection from a number of bacterial species. Symptoms may begin one to seven days after exposure to the bacteria. At least one-fourth of people who are infected are asymptomatic. Diagnosis is often based on symptoms and physical examination. Chest X-rays, blood tests, and culture of the sputum may help confirm the diagnosis.
Risk factors for haemopneumonia include cystic fibrosis, chronic obstructive pulmonary disease (COPD), asthma, diabetes, heart failure, history of smoking, older age, and a weak immune system.
Vaccines to prevent certain strains of haemopneumonia are available. Other methods include handwashing, social distancing, and wearing face coverings. Treatment depends on the severity of the case. Antibiotics are generally used to treat mild and moderate haemopneumonia cases, while hospitalization and oxygen therapy may be required for more severe cases. Tracheal suction, positive pressure ventilation, and blood transfusion may be necessary in acute episodes of bleeding or extreme cases. The survivability rate of late-stage haemopnuemonia if left untreated is under 30%, while survivability increases up to 85% through early medical intervention or intensive care.
Haemopnuemonia is widely believed to have been artificially created and engineered as a biological weapon by Velesan Yedinstate scientists. It was first identified during the First Velesan Civil War when an epidemic broke out in Trenshaya, the capital of the Velesan Council, in II.23995. Over the course of the epidemic, new strains developed and spread rapidly across the Velesan Council. The epidemic played a critical role in the outcome of the civil war. By III.100, the manmade origins of the disease was conclusively accepted by the scientific community within the Aidus system.